IO Biotech Announces Participation in Upcoming December Investor Conferences

Rhea-AI Summary

IO Biotech (Nasdaq: IOBT) announced participation in two December 2025 investor conferences: the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida on December 2, 2025, and the Piper Sandler 36th Annual Healthcare Conference in New York on December 3, 2025.

Mai-Britt Zocca, PhD, President & CEO, and Amy Sullivan, CFO, will take part in fireside chats and one-on-one investor meetings at both events. Webcasts will be available live and archived under the company’s Investors "News and Events" page for approximately 90 days. Provided webcast links are included for each event.

NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the Company’s participation in the 8^th Annual Evercore Healthcare Conference taking place in Florida on December 2, 2025, as well as the Piper Sandler Annual Healthcare Conference in New York on December 3, 2025. Mai-Britt Zocca, PhD, President & CEO, and Amy Sullivan, CFO, will participate in a fireside chat and host one-on-one meetings with investors at each conference.

Event: 8^th Annual Evercore Healthcare Conference
Location: Coral Gables, Florida
Fireside chat: Tuesday, December 2, 2025, at 7:55 am ET
Participants: Mai-Britt Zocca, PhD, President & CEO, and Amy Sullivan, CFO
Webcast Link: https://wsw.com/webcast/evercore52/iobt/2362844

Event: Piper Sandler 36^th Annual Healthcare Conference
Location: New York, New York
Fireside chat: Wednesday, December 3, 2025, at 3:00 pm ET
Participants: Mai-Britt Zocca, PhD, President & CEO, and Amy Sullivan, CFO
Webcast Link: https://event.webcasts.com/starthere.jsp?ei=1742757&tp_key=8b79a34402

Webcasts of the fireside chats may be accessed under “News and Events” in the Investors section of the IO Biotech website at www.iobiotech.com. Archived replays of the webcasts will be available for approximately 90 days following the events.

About IO Biotech

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, Cylembio®, in clinical trials, and additional pipeline candidates through preclinical development. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.

For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including statements regarding the timing or outcome of communications with regulatory authorities including the FDA, the timing or outcome of the submission of regulatory applications, including an IND for IO112, and statements regarding other current or future clinical trials, their timing, progress, enrollment or results, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

Contact:

Investors and media:
Maryann Cimino, Director of Investor Relations & Corporate Communications
IO Biotech, Inc.
617-710-7305
mci@iobiotech.com

FAQ

When will IO Biotech present at the Evercore Healthcare Conference (IOBT)?

The Evercore fireside chat is on December 2, 2025 at 7:55 am ET in Coral Gables, Florida.

When is IO Biotech's (IOBT) Piper Sandler fireside chat in New York?

The Piper Sandler fireside chat is on December 3, 2025 at 3:00 pm ET in New York.

Who will represent IO Biotech (IOBT) at the December 2025 conferences?

Mai-Britt Zocca, PhD, President & CEO, and Amy Sullivan, CFO will participate in the fireside chats and investor meetings.

Where can investors watch the IO Biotech (IOBT) conference webcasts?

Webcasts are available live and via archived replay under "News and Events" in the Investors section at www.iobiotech.com.

How long will IO Biotech (IOBT) archived webcasts be available after the events?

Archived replays will be available for approximately 90 days following each event.

What are the webcast links for IO Biotech's (IOBT) December 2025 presentations?

Evercore webcast: https://wsw.com/webcast/evercore52/iobt/2362844; Piper Sandler webcast: https://event.webcasts.com/starthere.jsp?ei=1742757&tp_key=8b79a34402.